{"i": ["placebo - controlled", "liposomal ciprofloxacin"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["Dual release ciprofloxacin for inhalation ( DRCFI ) contains liposomal ciprofloxacin"], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": ["DRCFI or placebo"], "o": []}
{"i": [], "o": ["change in sputum P aeruginosa bacterial density"]}
{"i": [], "o": ["safety and time to first pulmonary exacerbation"]}
{"i": ["placebo"], "o": ["P aeruginosa bacterial density"]}
{"i": ["DRCFI"], "o": ["time to first pulmonary exacerbation"]}
{"i": ["placebo"], "o": ["systemic adverse events", "tolerated", "pulmonary adverse events ."]}
{"i": ["DRCFI"], "o": []}
{"i": ["DRCFI"], "o": ["first pulmonary exacerbation", "tolerated"]}
{"i": [], "o": []}
{"i": ["Dual release ciprofloxacin for inhalation ( DRCFI ) contains liposomal ciprofloxacin"], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": ["DRCFI or placebo"], "o": []}
{"i": [], "o": ["change in sputum P aeruginosa bacterial density"]}
{"i": [], "o": ["safety and time to first pulmonary exacerbation"]}
{"i": ["placebo"], "o": ["P aeruginosa bacterial density"]}
{"i": ["DRCFI"], "o": ["time to first pulmonary exacerbation"]}
{"i": ["placebo"], "o": ["systemic adverse events", "tolerated", "pulmonary adverse events ."]}
{"i": ["DRCFI"], "o": []}
{"i": ["DRCFI"], "o": ["first pulmonary exacerbation", "tolerated"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["recombinant human DNase I nor tobramycin solution for inhalation ( TSI / TOBI )"], "o": []}
{"i": ["aminoglycoside antibiotics", "tobramycin", "gentamicin"], "o": []}
{"i": ["Dual release ciprofloxacin", "ciprofloxacin ."], "o": []}
{"i": [], "o": []}
{"i": ["liposomal ciprofloxacin ."], "o": []}
{"i": ["ciprofloxacin"], "o": ["lung clearance half life"]}
{"i": ["ciprofloxacin", "liposomal ciprofloxacin"], "o": []}
{"i": ["DRCFI"], "o": ["microbiological efficacy"]}
{"i": [], "o": ["safety , tolerability"]}
{"i": [], "o": ["respiratory AEs"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["ciprofloxacin"], "o": []}
{"i": [], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": [], "o": []}
{"i": ["DRCFI", "free ciprofloxacin", "liposomal ciprofloxacin"], "o": []}
{"i": ["control liposomes", "Matched placebo", "normal saline"], "o": []}
{"i": ["DRCFI or matching placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["spirometry , sputum collection , 6 min walk test ( 6MWT ) and St George ' s Respiratory Questionnaire ( SGRQ )."]}
{"i": [], "o": ["Sputum"]}
{"i": ["ciprofloxacin"], "o": []}
{"i": [], "o": ["colony forming unit ( CFU ) count"]}
{"i": ["placebo"], "o": ["sputum P aeruginosa bacterial density"]}
{"i": [], "o": ["time to first pulmonary exacerbation , forced expiratory volume in 1 s ( FEV1 ), 6MWT , SGRQ , safety and tolerability ."]}
{"i": [], "o": ["sputum production ( volume , colour , consistency or haemoptysis ), dyspnoea , cough , fever , wheezing , exercise tolerance ( or fatigue / lethargy / malaise ), FEV1 or FVC fall", "changes on chest radiograph and changes in chest sounds on auscultation ."]}
{"i": ["placebo"], "o": []}
{"i": [], "o": ["P aeruginosa bacterial load", "annual pulmonary exacerbations"]}
{"i": [], "o": []}
{"i": [], "o": ["Time to pulmonary exacerbation"]}
{"i": [], "o": []}
{"i": ["placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["Placebo"], "o": []}
{"i": [], "o": []}
{"i": ["Inhaled LA anticholinergic", "Inhaled SABA", "Combination inhalers ( ICS / LABA )", "macrolides", "SA anticholinergic", "Prednisone", "Inhaled LABA", "mannitol", "Inhaled corticosteroids"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["ciprofloxacin"], "o": []}
{"i": ["placebo"], "o": ["P aeruginosa bacterial density"]}
{"i": [], "o": []}
{"i": [], "o": ["bacterial density"]}
{"i": [], "o": ["sputum P aeruginosa bacterial counts"]}
{"i": [], "o": ["bacterial counts"]}
{"i": ["placebo"], "o": ["Pulmonary exacerbations"]}
{"i": [], "o": ["overall proportion of subjects requiring antibiotics for pulmonary exacerbation"]}
{"i": ["Intravenous antibiotics"], "o": []}
{"i": ["placebo"], "o": ["median time to pulmonary exacerbation"]}
{"i": ["placebo"], "o": ["FEV1", "6MWT distance", "SGRQ total score"]}
{"i": ["placebo"], "o": ["Failure to culture P aeruginosa"]}
{"i": ["placebo"], "o": ["New sputum pathogens"]}
{"i": [], "o": ["New sputum pathogens"]}
{"i": ["ciprofloxacin", "placebo"], "o": ["categorical susceptibility"]}
{"i": [], "o": ["P aeruginosa ciprofloxacin minimal inhibitory concentrations"]}
{"i": ["placebo"], "o": ["AEs", "tolerated"]}
{"i": [], "o": ["AEs"]}
{"i": ["placebo"], "o": ["sinusitis", "Respiratory - related AEs", "non - respiratory AEs"]}
{"i": ["placebo"], "o": ["headache", "product taste abnormal", "lung disorder", "nausea"]}
{"i": ["DRCFI"], "o": []}
{"i": [], "o": ["microbiological efficacy"]}
{"i": ["placebo - controlled"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["time to exacerbation"]}
{"i": ["DRCFI"], "o": []}
{"i": [], "o": ["pulmonary exacerbation rates"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["duration of drug exposure"]}
{"i": ["DRCFI"], "o": ["antimicrobial efficacy"]}
{"i": ["DRCFI", "placebo", "TOBI"], "o": ["exacerbations", "bacterial density", "respiratory - related AEs"]}
{"i": ["gentamicin10", "ciprofloxacin"], "o": ["bacterial density"]}
{"i": [], "o": []}
{"i": ["DRCFI"], "o": ["tolerated"]}
{"i": ["ciprofloxacin", "aminoglycosides"], "o": ["tolerability"]}
{"i": [], "o": ["quality of life", "exacerbation data and respiratory AEs"]}
{"i": ["macrolides"], "o": ["SGRQ scores"]}
{"i": ["ciprofloxacin"], "o": []}
{"i": ["DRCFI"], "o": []}
{"i": [], "o": []}
{"i": ["ciprofloxacin", "ciprofloxacin ."], "o": []}
{"i": ["DRCFI )", "inhaled antibiotics"], "o": []}
{"i": ["nebulised antibiotics"], "o": []}
{"i": [], "o": []}
{"i": ["ciprofloxacin"], "o": []}
{"i": ["ciprofloxacin", "non - fluoroquinolone ) antibiotics", "fluoroquinolone"], "o": []}
{"i": [], "o": []}
{"i": ["oral antipseudomonal therapy"], "o": []}
{"i": ["DRCFI"], "o": ["antipseudomonal microbiological efficacy"]}
{"i": ["antibiotics"], "o": ["pulmonary exacerbation outcomes"]}
{"i": [], "o": []}
